MedTrace Logo

Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru

NCT00164216 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 208

Last updated 2012-09-11

No results posted yet for this study

Summary

This is a study of the efficacy and effectiveness of combination therapy for malaria due to P. falciparum in the Loreto Department, Iquitos, Peru. The investigators will enroll subjects ≥ 1 year-old who have a diagnosis of uncomplicated malaria due to P. falciparum. Patients will receive a treatment regimen consisting of mefloquine (25 mg/kg per day for two days) and artesunate (12 mg/kg per day for three days). Patients will be divided into two groups: one will receive drugs under direct supervision and the other will be instructed on how to take the drugs by themselves. Clinical and parasitologic response will be monitored for a follow-up period of 28 days. The findings of this study will be used to guide the Ministry of Health in evaluating its national policy for P. falciparum malaria treatment.

Conditions

  • Malaria Falciparum

Interventions

DRUG

mefloquine plus artesunate

Sponsors & Collaborators

Principal Investigators

  • Alexandre Macedo de Oliveira, MD, MSc · Centers for Disease Control and Prevention

  • Wilmer Marquiño Quezada, MD · National Institute of Health, Peru

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Peru

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00164216 on ClinicalTrials.gov